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Aberrant activation of the Hedgehog (Hh) pathway is responsible for the onset and progression of several
malignancies. Small molecules able to block the pathway at the upstream receptor Smoothened (Smo) or
the downstream effector Gli1 have thus emerged recently as valuable anticancer agents.
Here, we have designed, synthesized, and tested new Hh inhibitors taking advantage by the highly
versatile and privileged isoflavone scaffold. The introduction of specific substitutions on the isoflavone's
ring B allowed the identification of molecules targeting preferentially Smo or Gli1. Biological assays
coupled with molecular modeling corroborated the design strategy, and provided new insights into the
mechanism of action of these molecules. The combined administration of two different isoflavones
behaving as Smo and Gli antagonists, respectively, in primary medulloblastoma (MB) cells highlighted
the synergistic effects of these agents, thus paving the way to further and innovative strategies for the
pharmacological inhibition of Hh signaling.
© 2018 Elsevier Masson SAS. All rights reserved.1. Introduction
The Hedgehog (Hh) pathway is a signaling cascade that plays a
crucial role in embryonic development and tissue homeostasis
[1,2]. Although in adults Hh signaling is activated during tissue
repairing and wound healing, its aberrant activation has been re-
ported to drive tumorigenesis and tumor progression in several
cancers [3]. Germline or somatic mutations of genes encoding Hh
pathway components have been identified in human and murine
basal cell carcinoma (BCC) and medulloblastoma (MB) [4e6].
Moreover a growing number of reports correlate uncontrolled Hhedicine, Sapienza University
gmail.com (M. Mori), lucia.
pplied Biosciences, ETH-Zür-
erland.
served.signaling with multiple cancers such as lung, breast, stomach,
pancreas, ovarian carcinoma and hematopoietic malignancies
[5,7e10]. Targeting the Hh signaling pathway with small molecule
modulators has thus emerged as a profitable anticancer strategy, as
also highlighted in recent reviews [11e15]. The largest part of Hh
modulators developed so far act as antagonists of the upstream
Smoothened receptor (Smo) [16e20], whereas only a few inhibitors
of the downstream effectors Glioma-associated oncogene homo-
logue (Gli) proteins have been disclosed, most of which acting by an
unclear or indirect mechanism of action [12,21e24]. Two Smo an-
tagonists, namely Vismodegib and Sonidegib, have been approved
by the Food and Drug Administration (FDA) in 2012 and 2015,
respectively, for the treatment of metastatic and locally advanced
BCC, while a number of additional Smo antagonists are currently
undergoing clinical evaluation [19,20,25]. However, the emergence
of drug-resistance [15,26e29], and the occurrence of aberrant Hh
activation downstream of Smo seriously limited the use of these
drugs, and raised some concerns on the efficacy of therapeutic
approaches that target Smo. Indeed, pharmacological modulation
of the final andmost powerful effector Gli1 is nowadays considered
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signaling in cancer [12]. However, only the Gli antagonist Arsenic
trioxide (ATO) has entered clinical evaluation so far [30]. It is
therefore widely accepted that novel Hh inhibitors acting through
different mechanisms of action than Smo antagonism, or able to
overcome drug resistance, are in high demand as therapeutic
candidates for the treatment of Hh-dependent tumors.
A significant contribution to the discovery of novel Hh inhibitors
is given by natural compounds [11,17,22,31,32]. The first Hh inhib-
itor ever discovered has been Cyclopamine, a steroidal alkaloid
isolated from plants of the Veratrum species [13,33]. Subsequently,
many natural compounds belonging to different chemical classes
have been identified and characterized as Hh inhibitors acting
through different mechanisms [11]. Of particular interest is the case
of isoflavones, a class of natural compounds particularly abundant
in plants of the Leguminosae family. The isoflavone nucleus consists
of two phenyl rings linked by a pyran ring to form an oxygenated
heterocyclic ring, resulting in the typical 15 carbon atoms (C6-C3-
C6) skeleton with three rings, labeled A, B and C (Fig. 1). Iso-
flavones have long received attention due to their interesting bio-
logical activity and multiple benefits to human health [34e36].
Furthermore, isoflavones have emerged as privileged structures for
Hh inhibition in multiple and independent works. The phytoes-
trogen Genistein (Fig. 1) has been first shown in 2010 to inhibit Hh
signaling in prostate cancer cells in vitro and in vivo either as food
supplement in combination with other flavonoids or as isolated
compound [37]. Then, several studies pinpointed the role of Gen-
istein as Hh inhibitor, showing particular efficacy against cancer
stem cells (CSCs) of prostate [38], gastric [39], and breast cancer
[40], even though its macromolecular target has not been eluci-
dated yet. In contrast, Daidzein (Fig. 1) has been found to suppress
Gli1 activation in human breast cancer cells by inhibiting the tumor
necrosis factor-a (TNF-a), which is known to activate Hh signaling
by enhancing Gli1 nuclear translocation and transcriptional activity
[41]. Recently, by screening a natural compounds library, our
research group has identified the prenylated isoflavone Glab-
rescione B (GlaB, Fig. 1) as direct inhibitor of Gli1/DNA interaction
endowed with significant anticancer efficacy in vitro and in vivo
against Hh-dependent MB and BCC [22]. The mechanism of action
of GlaB has been deeply characterized at the molecular level, thusFig. 1. Chemical structure of isoflavones that have been previously investigated as Hh
inhibitors.pointing to the druggability of Gli1/DNA interaction in the treat-
ment of Hh-dependent tumors. Moreover, chemical modifications
at the ring B of GlaB (Fig. 1) proved not effective in Hh inhibition.
This data highlights preliminary structure-activity relationships
(SAR) of GlaB, and identifies the relevant molecular determinants
for the inhibition of Gli1 binding to DNA and related transcriptional
activities.
Based on these evidences, here we exploit the versatility of the
isoflavone scaffold as well as its affinity for the Hh signaling
pathwaywith the aim to design, synthesize and test specific Smo or
Gli antagonists. We combined computational modeling, organic
synthesis, and biological evaluations in a concerted multidisci-
plinary strategy. Chemical derivatives sharing the isoflavone core
were designed and screened in silico against the 3D structure of
Smo and Gli1 available by X-ray crystallography studies [42e45]. A
new and more efficient route to synthesize these isoflavones was
established; selected compounds were tested for their functional
and biological efficacy. Since several current clinical studies on Hh
inhibitors are designed to test a combination between a FDA-
approved Smo antagonist and a cytotoxic anticancer agent (i.e.
Sonidegib in combination with Etoposide and Cisplatin,
clinicalTrial.gov identifier: NCT01579929), here we monitored for
the first time the synergistic effect of the combination between two
targeted isoflavones acting specifically at Smo or Gli.
Further, and yet unexplored, approaches to target the Hh
signaling pathway might be stimulated by this work, including the
design of multi-target Hh inhibitors according to the fashionable
polypharmacology principles.
2. Materials and methods
2.1. Chemistry
All non-aqueous reactions were performed under an argon at-
mosphere using flame-dried glassware and standard syringe/septa
techniques.
All absolute solvents were purchased as anhydrous grade from
Sigma Aldrich and used without further purification unless other-
wise stated. Solvents for extractions, flash column chromatography
(FC) and thin layer chromatography (TLC) were purchased as
commercial grade from Sigma Aldrich and used without further
purification unless otherwise stated. Reactions were magnetically
stirred and monitored by TLC performed on Merck TLC aluminum
sheets (silica gel 60 F254). Spots were visualized with UV light
(l¼ 254 nm). Chromatographic purification of products (FC) was
performed using Sigma Aldrich silica gel 60 for preparative column
chromatography (particle size 40e63 mm). Melting points (Mp)
were obtained in open capillary tubes using a Büchi melting point
apparatus B-545 and are uncorrected. 1H and 13C NMR spectrawere
recorded in CDCl3, acetone-d6, DMSO‑d6 or methanol-d4 on a
Bruker AV-400 400MHz spectrometer (operating at 400MHz for
1H and 100MHz for 13C) at room temperature and tetramethylsi-
lane (TMS) as internal standard. Chemical shifts (d) are reported in
parts per million (ppm) and are referenced to CHCl3 (d¼ 7.26 ppm
for 1H, d¼ 77.16 ppm for 13C), acetone (d¼ 2.05 ppm for 1H,
d¼ 29.84 ppm for 13C) DMSO (d¼ 2.50 ppm for 1H, d 39.52 ppm for
13C), or MeOH (d¼ 3.31 ppm for 1H, d 49.00 ppm for 13C). All 13C
NMR spectra were measured with complete proton decoupling.
Data for NMR spectra are reported as follows: s¼ singlet,
d¼ doublet, t¼ triplet, q¼ quartet, m¼multiplet, br¼ broad
signal, J¼ coupling constant in Hz. High-resolution mass spectra
(HRMS) were recorded on Bruker BioApex Fourier transform ion
cyclotron resonance (FT-ICR) mass spectrometer. HPLC analysis was
performed on a Waters 2690 Separation Module, equipped with a
Rheodyne Model 8125 20-mL injector and a Model M486
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data were collected and processed using the Empower Chroma-
tography Manager software. Column: Phenomenex Luna C18, 5 mm
(250 4.6mm); eluent A) H2O/CH3CN, 95:5 v/v, eluent B) H2O/
CH3CN, 5:95 v/v; gradient elution: for 0e5min A:B¼ 50:50;
5e20min up to 100% B; 20e25min to 100% B; flow rate: 1.0mL/
min; UV detection at 295 nm. The purity of the compounds was
always higher than 95%.
General procedure for the preparation of deoxybenzoines
(3a-d). In a two-neck round-bottom flask a mixture of 3,5-
dimethoxyphenol (1) (6mmol, 1.00 equiv.), 3,4-disubstituted-
phenylacetic acid (2a-d) (6mmol, 1.00 equiv.) and BF3Et2O
(48mmol, 8.00 equiv.) was stirred at 90 C for 90min under argon.
The reactionmixturewas poured into 10% aqueous NaOAc (100mL)
and allowed to stir at room temperature for 24 h, forming a brown
precipitate. The precipitate was filtered and washed with H2O
(2 20mL). The precipitate was resuspended with EtOAc, dried
over Na2SO4 and finally concentrated in vacuo. The residue was
purified by FC using a mixture of Petroleum Ether/EtOAc as eluent,
to obtain the corresponding deoxybenzoin (3a-d) (Supplementary
Material).
General procedure for the Vilsmeier-Haack reaction for the
preparation of isoflavones (4a-d). In a two-neck round-bottom
flask a solution of deoxybenzoin (3a-d) (3mmol, 1.00 equiv.) in
DMF (5mL) was cooled to 0 C and BF3$Et2O (9mmol, 3.00 equiv.)
was added dropwise under argon. In another flask, DMF (8mL) was
cooled to 0 C and PCl5 (4.5mmol, 1.50 equiv.) was added. The
mixture was then allowed to stir at 55 C for 20min. The light
yellow colored solution containing N,N0-dimethyl (chloro-
methylene)ammonium chloride was then added to the above re-
action mixture at 0 C. The mixture was stirred at room
temperature for 2 h under argon and then poured into 0.1 N
methanolic HCl (70mL) and allowed to stir at 70 C for 2 h. After
removing the solvents in vacuo, H2O (50mL) and EtOAc (50mL)
were added and the aqueous phase was extracted with EtOAc
(3 100mL). The combined organic layers were washed once with
brine (100mL), dried over Na2SO4, and finally concentrated under
reduced pressure. The residue was purified by FC using Petroleum
Ether/EtOAc as eluent, to give the corresponding isoflavone (4a-d)
(Supplementary Material).
General procedure for the alkylation/benzylation reaction
(5e19). To a solution of the isoflavone (4a-d) (0.18mmol, 1.00
equiv.) in acetone (5mL), K2CO3 (1.8mmol,10.00 equiv.) was added.
After stirring for 15min the corresponding alkyl/benzyl bromide
(0.9mmol, 5.00 equiv.) was added drop wise to the mixture and
stirred at 45 C overnight. After removing the acetone in vacuo, H2O
(10mL) and EtOAc (20mL) were added and the aqueous phase was
extracted with EtOAc (3 20mL). The combined organic layers
were dried over Na2SO4, and finally concentrated under reduced
pressure. The residue was purified by FC using Petroleum Ether/
EtOAc as eluent to give the corresponding substituted-isoflavone
(5e19) (Supplementary Material).
2.2. Molecular modeling
Molecular modeling simulations were performed as reported
previously against both targets. Briefly, molecular docking to Gli1ZF
was carried out by GOLD docking program (version 5.0.1) [46,47]
using the crystallographic structure of Gli1ZF in complex with DNA
as rigid receptor (PDB 2GLI) [43]. Docking settings have been
described previously [22]. Molecular docking to the Smo receptor
was carried out by FRED docking program (version 3.0.1) using the
crystallographic structure of Smo in complex with the natural
product antagonist cyclopamine (PDB 4O9R). Docking settings have
been described previously [17].2.3. Biology
Cell cultures, transfection and treatments. Shh-Light II, MEFs WT,
SuFu/ MEFs and Smo/ MEFs were cultured in DMEM plus 10%
FBS, antibiotics and L-glutamine. Murine MBs were freshly isolated
from Ptch ± mice (The Jackson Laboratory, Bar Harbor, ME, USA/
EMMA, Monterotondo, Italy) as previously described [48]. Cells
were cultured in Neurobasal Media-A with B27 supplement minus
vitamin A [49]. Mycoplasma contamination in cell cultures was
routinely detected by using PCR detection kit (Applied Biological
Materials, Richmond, BC, Canada). Transient transfections were
performed using DreamFect™ Gold transfection reagent (Oz Bio-
sciences SAS, Marseille, France). Cells were treated with SAG
(200 nM, Alexis Biochemicals Farmingdale, NY, USA). Vismodegib
was purchased from Selleckchem.com (Munich, Germany).
Hh-dependent luciferase reporter assay. The luciferase assay was
performed in Shh-Light II cells, stably incorporating a Gli-
responsive luciferase reporter and the pRL-TK Renilla (Normaliza-
tion control), treated for 48 h with SAG (200 nM) and the studied
compounds. Luciferase and Renilla activity were assayed with a
dual-luciferase assay system according to the manufacturer's in-
struction (Biotium Inc., Hayward, CA, USA). Results are expressed as
Luciferase/Renilla ratios and represent the mean± SD of three in-
dependent experiments, each performed in triplicate.
mRNA expression analysis. Total RNA was isolated with TRIzol
(Thermo Fisher Scientific) and reverse-transcribed with SensiFAST
cDNA Synthesis Kit (Bioline Reagents Limited, London, UK). Quan-
titative real-time PCR (Q-PCR) analysis of Gli1, Gli2 and HPRTmRNA
expression was performed on each cDNA sample using the ViiA™7
Real-Time PCR System employing Assay-on-Demand Reagents (Life
Technologies, Foster City, CA, USA). A reaction mixture containing
cDNA template, SensiFAST Probe Lo-ROX Kit (Bioline Reagents
Limited) and primer probe mixture was amplified using FAST Q-
PCR thermal cycler parameters. Each amplification reaction was
performed in triplicate and the average of the three threshold cy-
cles was used to calculate the amount of transcript in the sample
(using SDS version 2.3 software). mRNA quantification was
expressed, in arbitrary units, as the ratio of the sample quantity to
the calibrator. All values were normalized with the endogenous
control HPRT.
Statistical analysis. Statistical analysis was performed using the
StatView 4.1 software (Abacus Concepts, Berkeley, CA, USA). Sta-
tistical tests were appropriately chosen for each experiment. For all
other experiments, P-values were determined using Student's t-test
and statistical significance was set at P< 0.05. Results are expressed
as mean± SD from an appropriate number of experiments (at least
three biological replicates).
3. Results and discussion
3.1. Computational design of isoflavones targeting Smo or Gli1
In a previous study, a number of GlaB chemical derivatives
(DBG1-5, Fig. 1) bearing modifications to the ring B have been
synthesized and tested as Hh inhibitors [22], showing no effects.
These data clearly highlighted the pharmacophoric relevance of the
substitutions at the isoflavone's ring B in binding to Gli1 and pre-
venting its interaction to DNA. Therefore, herewe designed a small-
size focused library of isoflavones bearing different substituents in
different positions of the ring B. Molecules were then tested in silico
for the interaction with the heptahelical bundle of Smo or the DNA
binding site of Gli1. To this aim, the computational protocols
already established and validated in previous works were used
[17,18,22,23,50]. Results unequivocally show that, for most of tested
compounds, the O-substitution at para position of ring B is
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tution at meta position is preferred to interact with Gli1. This
peculiar behavior could be explained by analyzing the shape of the
binding sites on Smo or Gli1. Indeed, the canonical binding site of
Smo is narrow and is elongated within the heptahelical bundle of
the receptorwith a linear geometry, while the binding site of Gli1 at
the interface between zinc fingers (ZF) ZF4 and ZF5 is solvent
exposed and slightly bended compared to the site in Smo.
Based on molecular modeling suggestions, we decided to syn-
thesize the compounds listed in Table 1 (namely, the intermediate
4c, and the final compounds 5e19) to investigate their effects on
the modulation of Hh signaling. To depict structural determinants
responsible for specific binding to each target, the same sub-
stituents were introduced, where possible, at meta position of ring
B to target preferentially Gli1, or at para position of ring B to target
preferentially Smo.3.2. Chemistry
Several synthetic procedures have been complied for the prep-
aration of isoflavones [51]. Most of them have major drawbacks,
including the use of special and expensive reagents in large excess,
long reaction times, vigorous conditions and very low yields. We
previously provided a synthetic route for the total synthesis of GlaB
featuring six-step with an overall yield of 7% [52], based on a
palladium catalyzed cross coupling reaction of 3-iodochromone
with the corresponding arylboronic acid. However, this approach
is overall unfeasible for the synthesis of GlaB-ring B derivatives, due
to the challenging mono-functionalization of the two hydroxyl-
groups in ring B. This prompted us to develop a mild and cost
effective method, inspired by the so called deoxybenzoin route
[53], which would allow the preparation of isoflavones bearing
different substituents on meta and para positions of ring B. In this
case, the isoflavone moiety was built in only two steps, involving
first a Friedel-Crafts acylation and then a Vilsmeier-Haak reaction
(Scheme 1). Suitably substituted phenyl acetic acids (2a-d) are
fundamental to achieve the synthesis of free meta- or para-hy-
droxyl groups in ring B. The late stage functionalization of those
accomplished the preparation of a small library of GlaB-ring BTable 1
Chemical structure of isoflavone derivatives investigated in this work as Hh in-
hibitors.
Cmpd R1 R2 Cmpd R1 R2
GlaB -OPrenyl -OPrenyl 12 -Op-BnCF3 -OCH3
4c -OH -H 13 -OCH3 -Op-BnCF3
5 -OPrenyl -OCH3 14 -Op-BnCF3 -H
6 -OCH3 -OPrenyl 15 -OBn -OBn
7 -OPrenyl -H 16 -Op-BnCN -OCH3
8 -OBn -OCH3 17 -Op-BnCOOCH3 -OCH3
9 -OCH3 -OBn 18 -Op-BnCOONH2 -OCH3
10 -OGeranyl -OCH3 19 -Op-BnNO2 -OCH3
11 -OCH3 -OGeranylderivatives meta- or para-substituted (5e19) (Table 1), ready to be
tested against the Hh pathway by means of functional assays, as
described below.
3.3. Hh inhibition by newly synthesized isoflavones
The Hh inhibitory properties of synthesized compounds were
investigated in a luciferase reporter assay, which is widely used for
characterizing Hh antagonists. To this end, NIH3T3 Shh-Light II cells
stably incorporating a Gli-responsive firefly luciferase reporter (Gli-
RE) and the pRL-TK Renilla as normalization control, were treated
with the synthetic Smo agonist SAG alone or in combination with
the selected molecules, to evaluate their ability to suppress Hh
signaling. Among the tested molecules with the presence of a
substituent atmeta position of the ring B, compounds 4c, 14, 16, 17,
18 and 19 showed mild activity at the maximum concentration of
30 mM; 5, 8, 10, and 12 showed high activity with an IC50 ranging
from 2 to 4 mM; 7was inactive (Table 2 and SupplementaryMaterial
Figure S1A and Figure S2). Among molecules with the presence of a
substituent at para position of the same ring, compounds 13 and 15
showed high activity as Hh inhibitors with an IC50 of 3.4 mM and
0.29 mM, respectively; 6 and 9 showed mild activity, while 11
proved to be toxic (data not shown), as observed by a significant
modulation of the internal control Renilla (Table 2 and
Supplementary Material Figure S1B).
3.4. Specificity of Smo and Gli antagonists
To investigate the functional activity of the most active com-
pounds as Gli1 or Smo modulators, we exploited the Gli1-
dependent luciferase reporter screening assay, in which mouse
embryonic fibroblasts (MEFs) expressing ectopic Gli1 were treated
with increasing concentrations of the selected small molecules.
According to computational and experimental studies, compounds
5 and 12 proved to be the most powerful in inhibiting Gli1 activity,
with an IC50 value between 5 and 11 mM (Fig. 2 and Table 2). The
FDA approved Smo antagonist Vismodegib (GDC-0449) was used as
control to validate the assay method and, as expected, it showed no
effect on Gli1 transcriptional activity (Supplementary Material
Figure S2).
The ability of 5 and 12 to target Gli1 was confirmed in Smo/
MEFs transfected with ectopic Gli. As shown in Fig. 3, compounds 5
and 12 inhibited the luciferase activity driven by a Gli-responsive
element (Fig. 3A), while compounds 13 and 15 did not (Fig. 3B).
To further prove that compounds 5 and 12 operate downstream of
Smo, we test such molecules in SuFu/ MEFs, in which the
constitutive activation of the Hh pathway is due to the loss of the
Gli negative regulator SuFu. In this cellular context, compounds 5
and 12 significantly reduced the constitutive endogenous expres-
sion of Gli1 and Gli2, the final effectors of the Hh signaling (Fig. 3C).
As expected, compounds 13 and 15 fail in inhibiting Hh target gene
expression because pathway activation occurs downstream of Smo
receptor (Fig. 3D).
Overall, biological results are clearly in agreement with
computational modeling predictions, showing that isoflavones
bearing a substituent at para position of ring B target preferentially
the upstream receptor Smo, whereas those bearing a substituent at
meta position of ring B act mostly at the level of the downstream
effectors Gli. The only exception to this rule is represented by
compound 15, which bears a double bulky aryl substitution to the
ring B and behaves as specific Smo antagonist. Notably, 15 is the
most potent Hh inhibitor identified in this work, and was therefore
investigated as Smo antagonist together with 13. The two most
potent Gli antagonists, namely 5 and 12, were further investigated
as well.
Scheme 1. Deoxybenzoin approach for the synthesis of GlaB-ring B derivatives: i) BF3$OEt2, 90 C, 90min 50e60%; ii) BF3$OEt2, (chloromethylene)dimethyliminium chloride, DMF,
rt, 2 h 28e32%; iii) alkyl- or benzyl-bromide, K2CO3, acetone, 45 C, 17 h, 88e95%.
Table 2
IC50 values for selected compounds in the Shh-Light II cells and in MEFs assays.
Substitution at meta position
Shh-Light II IC50 (mM) MEFs IC50 (mM)
5 2.87± 0.33 5.695± 0.84
8 3.719± 0.88 17.12± 0.87
10 3.61± 0.31 21.22± 1.21
12 2.58± 0.12 11.50± 0.85
16 16± 1.1 nd
17 >30 nd
18 >30 nd
19 >30 nd
4c >30 nd
7 >30 >20
14 10.47± 0.73 26.73± 1.7
Substitution at para position
Shh-Light II IC50 (mM) MEFs IC50 (mM)
6 6.97± 0.67 10.7± 1.01
9 6.921± 0.76 39.2± 2.03
11 nd nd
13 3.477± 0.66 55.29± 2.57
15 0.29± 0.12 57.74± 3.98
nd: not determined.
Fig. 2. Specificity of Smo and Gli antagonists. Inhibition of Gli1-induced transcription
was assessed in MEFs transfected with 12XGliBS-Luc and pRL-TK Renilla (normaliza-
tion control) plus control (empty) or Gli1 vector and treated with increasing concen-
trations of selected compounds with a substituent at meta (A) or at para (B) position of
ring B. Treatment time was 24h; control cells were treated with DMSO only. In all
experiments data show the mean ± SD of three independent experiments: (*) P < 0.05
vs CTR (DMSO); (**) P < 0.01 vs CTR (DMSO).
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The possible binding mode of the most interesting Hh inhibitors
towards Smo or Gli1 crystallographic structure was investigated by
molecular modeling simulations. It is worth noting that previous
studies performed by our research group highlighted the reliability
of computational tools in predicting the binding mode of Gli1 an-
tagonists (i.e. the docking-based binding mode of GlaB was sup-
ported by multiple experimental evidences) [22], and Smo
antagonists (the docking pose of Vismodegib was subsequently
confirmed by X-ray crystallography studies) [44,50]. Therefore,
these established computational protocols were used herein to
dock 5 and 12 towards Gli1 zinc-finger (ZF) domain (Gli1ZF) and to
dock 13 and 15 within the heptahelical bundle of Smo. Two
different docking programs were used (i.e. GOLD to dock against
Gli1, and FRED to dock against Smo) according to the differentshape and features of the binding sites, as well as to prior bench-
marking studies mentioned above.
Fig. 3. Specificity of Smo and Gli antagonists. (A, B) Inhibition of Gli1-induced transcription was assessed in Smo/ MEFs transfected with 12xGliBS-Luc and pRL-TK Renilla (as
normalization control) plus control (empty) or Gli1 vector, and treated for 24 h with increasing concentration of Gli1- (A) or Smo- (B) antagonists, or with DMSO only as control. (C,
D) SuFu/ MEFs were treated for 48h with Gli1- (C) or Smo- (D) antagonists, or DMSO as a control. Gli1 and Gli2 mRNA levels were determined by qRT-PCR normalized to HPRT
expression. In all experiments data show the mean ± SD of three independent experiments: (*) P<0.05;(**) P < 0.01vs CTR (DMSO).
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share a highly comparable binding mode each other, with the iso-
flavone core occupying a surface region at the interface between
ZF4 and ZF5 (Fig. 4). In particular, the core establishes H-bond in-
teractions with Lys350, which has been previously highlighted by
mutagenesis studies to be a key determinant for Gli1 transcrip-
tional activity [22], with Thr355, Lys360, and the Zn-binding
His351, (Fig. 4). The isoflavone ring B is docked in a pose that
hides the nuclear localization system (NLS) in correspondance of
residue Thr374 to the solvent area [54]. The isoprenyl group linked
to the ring B in 5 is docked in a groove near Ser357 and Asn358
(Fig. 4A), while the aromatic moiety of 12 is projected towards theFig. 4. Predicted binding mode of Gli1 antagonists. The docking pose of 5 (A) and 12 (B) is s
ligands are showed as lines. Residues H-bonded or stacked to the ligands are showed as stick
are showed as magenta dashed lines, Zn(II) ions as grey spheres. (For interpretation of the re
article.)ZF5where it interacts with the side chain of Tyr373 bymeans of a T-
shaped p-p stacking interaction (Fig. 4B). These binding modes are
highly comparable to that of GlaB even though the isoflavone core
is oriented in a slightly different manner [22], and account for a
direct competition between these Gli1 antagonists and DNA.
In the case of Smo, both 13 and 15 are able to fit the narrow
lipophilic site located within the heptahelical bundle of the re-
ceptor, and to interact with key residues already highlighted in
structural and computational studies. Different than Gli1, the iso-
flavone core of the Smo antagonists binds in two different confor-
mations, which are most likely biased by the presence of two bulky
aryl substituents on the ring B of 15 compared to the singlehown as yellow sticks. Gli1ZF is shown as green cartoon. Residues within 5Å from the
s, and are labeled. Residues numbers correspond to the full length human Gli1. H-bonds
ferences to color in this figure legend, the reader is referred to the Web version of this
Table 3
Percentage of growth inhibition of primary MB cells freshly isolated from Ptch ±
mice, after 72 h of treatment with the selected compounds.
[mM] GlaB 5 12 13 15
0.125 28.6± 2.7 5.9± 3 37.7± 3.1 20.8± 5.3 33.3± 3.8
0.25 42.4± 3.1 26.3± 4 40.6± 2.3 23.5± 3.1 44.2± 4.9
0.5 46.6± 3.4 29.2± 3.6 44.52± 3.6 32.5± 1.3 51.4± 5.1
1 55.9± 4 35.6± 2.1 50.9± 4.8 51.8± 3.5 61.2± 4.8
5 65.1± 5.3 55.4± 5 54± 5 54.2± 4.4 66.6± 4.1
S. Berardozzi et al. / European Journal of Medicinal Chemistry 156 (2018) 554e562560substituent at para position of ring B of 13 (Fig. 5).
The isoflavone core of 13 binds deeply in a region of Smo that is
occupied by multiple antagonists, as elucidated by X-ray crystal-
lography [17,28,42,44,45], and establishes H-bond with Arg400 and
Tyr394 (Fig. 5A), this latter being p-p stacked to the compound.
Another p-p stacking interaction is established by 13 with the side
chain of Phe484. As already observed in other Smo antagonists, the
trifluoromethyl group is docked near the entrance of the binding
site in correspondence of the extracellular portion of Smo, whereas
lipophilic moieties are preferentially docked within the intra-
membrane region of the receptor [42,55]. This pharmacophoric
preference might also explain why, in the case of 15, the isoflavone
core binds with opposite orientation near the extracellular region
of Smo. Indeed, ring B is substituted with two hydrophobic ben-
zyloxy groups that are projected deeply in the heptahelical bundle
of Smo in close proximity to non-polar residues such as Phe222,
Met230, Trp281, Phe391, His470, Leu515, and Leu522. Among them,
His470 establishes a T-shaped p-p interaction with the benzyloxy
group substituted at para position of ring B (Fig. 5B). The compound
also establishes H-bond interactions with Asn219, Gln477, and
Tyr394, this latter becoming p-p stacked to the ring B.
Overall, the binding modes predicted by molecular modeling
towards Gli1 and Smo are supportive of the interaction of these
isoflavones with their respective targets, as well as of the specific
mechanism of Hh inhibition.Table 4
Percentage of growth inhibition in primary MB cells freshly isolated from Ptch ±
mice, after 72 h of treatment with the binary combination of a Gli1-and a Smo-
antagonist.
[mM] 12 þ 13 12 þ 15 5 þ 13 5 þ 15 GlaB þ 13 GlaB þ 15
0.125 44.2± 2.7 35.5± 5 31.8± 2.7 32.0± 4.6 33.5± 1.1 38.3± 4.7
0.25 50.1± 2.9 50± 3.7 33± 2 34± 2.1 53.1± 2.5 63.4± 3.1
0.5 53.5± 3.9 55.2± 4.6 35± 3.3 40± 3.6 60.1± 1.6 70± 4.2
1 61.9± 3.4 67.9± 3.8 45.7± 3 51.9± 2.7 nd nd
2 58.6± 4 68.2± 1.3 47.1± 1.5 60.4± 1.5 nd nd
nd: not determined.3.6. Synergistic combination of isoflavone Smo and Gli antagonists
Hh pathway alteration through a ligand-dependent or inde-
pendent mechanism is a key driver in tumorigenesis. For this
reason, the development of Hh inhibitors is eliciting great interest
in drug discovery. Events as drug resistance or the presence of by
stander co-regulatory mechanism of the Hh pathway, highlight the
necessity to discover new effective Hh inhibitors for cancer therapy.
To this end, the synergistic effect elicited by two isoflavones
targeting specifically Smo or Gli1 was tested. The ability to inhibit
Hh-dependent tumor growth was analyzed in primary MB cells
that were freshly isolated from Ptch ± mice tumors and tested in
short-term cultures to keep Hh sensitivity in vitro [4]. As shown in
Table 3 (Supplementary Material Figure S4), single compoundFig. 5. Predicted binding mode of Smo antagonists. The docking pose of 13 (A) and 15 (B) is
ligands are showed as lines. Residues H-bonded or stacked to the ligands are showed as st
bonds are showed as magenta dashed lines. (For interpretation of the references to color itreatments inhibited the cell growth with comparable potency to
the reference isoflavone Hh inhibitor GlaB.
In contrast, the binary combination between a Smo (13 or 15)
and a Gli1 (5 or 12 or GlaB) antagonist impaired cell proliferation at
noticeably lower concentrations (Table 4, and Supplementary
Material Figure S5). Indeed, we observed a similar inhibition on
cell growth in primary MB cells treated with GlaB alone at the
concentration of 0.5 mM (46% growth inhibition, Table 3), compared
to binary combination of compounds 12 and 13 at the final con-
centration of 0.125 mM (Table 4).
The binary combination of GlaB with compound 13 or com-
pound 15 at the concentration of 0.25 mM showed 53% and 63.4%
Hh-dependent tumor growth inhibition, respectively. The most
powerful effect was achieved by the combined treatment with GlaB
and compound 15 at the concentration of 0.5 mM,which displayed a
70% cell growth inhibition (Table 4 and Supplementary Material
Figure S5).shown as yellow sticks. Smo is shown as green cartoon. Residues within 5Å from the
icks, and are labeled. Residues numbers correspond to the full length human Smo. H-
n this figure legend, the reader is referred to the Web version of this article.)
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Hh pathway at both upstream and downstream levels stands by as a
new and more effective strategy to repress the Hh-dependent tu-
mor growth.
4. Conclusion
Abnormal Hh activation is a hallmark of many cancers, and
several germline or somatic mutations in Hh pathway components,
have been documented in BCC, MB, rhabdomyosarcoma (RMS),
meningioma, and many other tumors. Pharmacological Hh inhibi-
tion has emerged as a valuable anticancer strategy as underlined by
Vismodegib and Sonidegib, two Smo antagonists approved by the
FDA in 2012 and 2015, respectively, for the treatment of metastatic
or locally-advanced BCC [19]. However, drug-resistant mutations
occurring at the Smo receptor as a consequence of pharmacological
pressure, coupled with Hh activation downstream or indepen-
dently of Smo, have raised the need to identify novel strategy to
inhibit Hh signaling [12,29]. In this regard, one of the most prom-
ising Hh target is the final and most powerful effector Gli1, whose
druggability has been assessed by means of the isoflavone GlaB
[22], and the synthetic molecule GANT-61, although this latter
suffers from chemical instability as substantiated recently [23,56].
Since the isoflavone emerged as privileged scaffold in Hh inhi-
bition, based on molecular modeling predictions and prior studies
[17,22], here we designed a number of isoflavones able to interact
preferentially with the Smo receptor or the Gli protein. Molecules
were synthesized by means of a novel synthetic pathway, and were
tested in vitro. Experimental results confirmed molecular modeling
predictions, showing that isoflavones substituted in meta to the
ring B bind preferentially to Gli1ZF domain, whereas isoflavones
substituted in para position bind preferentially the Smo receptor.
Notably, molecules were also able to inhibit Hh-dependent tumor
growth in primary MB cells at sub-micromolar concentration.
Compared to GlaB, the combined administration of a Smo and a
Gli antagonist provided similar Hh inhibition effects with individ-
ual doses of compounds 12 and 13 decreased by four times (0.5 vs
0.125 mM) even though the strongest Hh inhibitionwas achieved by
the combination of GlaB and 15 at the concentration of 0.5 mM (70%
inhibition vs 46% inhibition by GlaB alone at 0.5 mM).
As highlighted by a recent survey on active anticancer clinical
trials (data not shown) and literature reports [57e59], combination
of two (or more) drugs with documented high single-agent
response rates and distinct mechanisms of action is expected to
be more effective than administration of either agent alone. Target
therapy based on binary drugs combinations became a paradigm
particularly in anticancer drug development, not only to increase
efficacy, but also to decrease toxicity of individual anticancer
agents. Despite Hh inhibitors are combined in clinical trials with
conventional anticancer agents, our data highlighted that targeting
specifically Hh pathway at both upstream and downstream levels
through the combination of a Smo with a Gli antagonist efficiently
enhance Hh inhibition at lower individual compounds doses. Even
though additional studies are needed to evaluate the ADME profile
of these compounds, particularly with respect to possible drug-
drug interactions, we expect that our study might trigger addi-
tional investigations on clinically relevant Hh inhibitors, and
encourage the treatment of Hh-dependent tumors with combina-
tion therapy.
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